Vial Revenue and Competitors

Location

N/A

Total Funding

Health

Industry

Estimated Revenue & Valuation

  • Vial's estimated annual revenue is currently $62.1M per year.(i)
  • Vial's estimated revenue per employee is $297,000

Employee Data

  • Vial has 209 Employees.(i)
  • Vial grew their employee count by 8% last year.

Vial's People

NameTitleEmail/Phone
1
Co-Founder and CEOReveal Email/Phone
2
Co-Founder & Board ObserverReveal Email/Phone
3
Director, Contracts & Legal AffairsReveal Email/Phone
4
Director FinanceReveal Email/Phone
5
Director, Contracts & Legal AffairsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$14.3M599%N/AN/A
#2
$179.6M5327%N/AN/A
#3
$6.5M303%N/AN/A
#4
$5.3M28-3%N/AN/A
#5
$12.4M5128%N/AN/A
#6
$13.6M56-10%N/AN/A
#7
$6.5M30-12%N/AN/A
#8
$18M746%N/AN/A
#9
$10.2M472%N/AN/A
#10
$181.6M53813%N/AN/A
Add Company

What Is Vial?

Vial is a clinical trial site-in-a-box for clinics. Vial partners with clinics that don't currently run clinical trials and turns them into $500k/yr+ high-efficiency, tech-enabled research sites.

keywords:N/A

N/A

Total Funding

209

Number of Employees

$62.1M

Revenue (est)

8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vial News

2022-04-19 - Suspect hands MNPD officer vial of crack rocks

Suspect hands MNPD officer vial of crack rocks ... NASHVILLE, Tenn. (WKRN) — A 60-year-old man was taken into custody Sunday night after police...

2022-04-17 - Class 4 Medicines Defect Information: Pfizer Limited, Depo ...

MDR 240-03/22. Company name. Pfizer Limited. Product description. Depo-Medrone with Lidocaine 40 mg/mL (1 mL and 2 mL vials – single vial...

2022-04-17 - Aptar CSP Technologies Expands Production of Activ-Vial ...

Bringing local production of Activ-Vial™, the world choice for blood glucose test strip protection, to diabetes patients in the China region...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$31.5M20912%$220.7M
#2
$34.5M2092%N/A
#3
$31.5M20930%N/A
#4
$45.4M209-13%$155M
#5
$33.3M2095%N/A